RT @RichardPAConway: SAPHYR trial of sarilumab for relapsing PMR @profbdasgupta et al. Sarilumab+14 week steroids vs 52
Tweet Content
SAPHYR trial of sarilumab for relapsing PMR @profbdasgupta et al. Sarilumab+14 week steroids vs 52 week steroid monotherapy. Sustained remission 28.3% vs 10.3% P=0.0193. Flare after remission 16.7% vs 29.3% HR 0.56 (0.35–0.90) P=0.0158 @RheumNow #EULAR2022 https://t.co/oopWKjciWG https://t.co/xi4ELJiCXa
Links
EULAR Abstract Archive
http://scientific.sparx-ip.net/archiveeular/index.cfm?searchfor=LB0006&c=a&view…
Show on Archive Page
On
Display in Search Results
On
PDQ
Off